DBV Technologies Announces 2-Year Results From Ongoing Phase 3 Open-Label Extension To The EPITOPE Trial Of Viaskin Peanut In Toddlers
Portfolio Pulse from Benzinga Newsdesk
DBV Technologies has announced positive interim results from its ongoing Phase 3 Open-Label Extension to the EPITOPE Trial of Viaskin Peanut in toddlers. The treatment showed improvement across all efficacy parameters between months 12 and 24. Notably, 81.3% of subjects reached an eliciting dose of ≥1,000 mg after 24 months of treatment. There were no treatment-related anaphylactic or serious treatment-related adverse events in the second year of active treatment. The company will present these results at the American College of Allergy, Asthma, and Immunology annual meeting.
November 09, 2023 | 11:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DBV Technologies' positive interim results from its ongoing Phase 3 trial of Viaskin Peanut in toddlers could potentially boost investor confidence in the company's research and development capabilities. The absence of serious adverse events also bodes well for the safety profile of the treatment.
Positive clinical trial results often lead to increased investor confidence as they indicate progress in the company's research and development efforts. The absence of serious adverse events also suggests a good safety profile for the treatment, which could potentially lead to regulatory approval and commercial success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100